Completion of enrollment marks significant milestone in progression of heart failure clinical program and included the largest number of participants to date to receive AB-1002 AskBio Inc. (AskBio), a ...
Final participant randomized in the GenePHIT Phase 2 clinical trial assessing safety and efficacy of AB-1002 for adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III ...
Diamyd Medical today announced the completion of a pre-specified interim efficacy analysis on C-peptide in the ongoing pivotal Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in individuals ...
In May 2025, Sandvik announced that restructuring measures of approximately SEK 3 billion will be implemented in business area Machining between 2025-2030 to strengthen operational efficiency, margin ...
Final participant randomized in the GenePHIT Phase 2 clinical trial assessing safety and efficacy of AB-1002 for adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III ...
Hello, and welcome to this market update with the Swedish Diabetes Research Company, Diamyd Medical. On Friday evening, the company announced negative interim results from its Phase III study. We will ...
AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced that the randomization of the last participant was completed earlier this ...
Quantum dot–based time-bin QKD achieves stable, long-distance secure communication with practical performance.
MADISON, Wis. -- The Madison School District kicked off construction for two new projects at some of its schools. One project is for Sherman Middle and Malcolm Shabazz City High Schools. The other is ...
The first site to be activated in the trial is Monash Children’s Hospital, one of Australia’s leading paediatric medical and research facilities, which is now open for patient screening and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results